All In Biotech

Drug Trial Radar · NCT01313650

A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Aug 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,538 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,538

Actual

Start

Mar 1, 2011

Primary completion

Apr 1, 2012

Study completion Apr 5, 2012

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation Powder and Placebo when administered once-daily via a Novel Dry Powder Inhaler over a 24-week treatment period in subjects with COPD. Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to14 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 27 weeks. A subset of subjects at selected sites will also perform 24-hour serial spirometry and Holter monitoring during the study and provide serial blood samples for pharmacokinetic analysis. Sparse pharmacokinetic sampling for population pharmacokinetic analyses will be obtained from non-subset subjects. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) FEV1 on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, clinical laboratory tests, and 24 hour Holter monitoring (subset only).

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • 62.5/25mcgDrug

    GSK573719/GW64244

  • 62.5mcgDrug

    GSK573719

  • 25mcgDrug

    GW642444

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)Time frame: Baseline and Day 169

Locations

165 sites in 13 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Ormond Beach, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Lawrenceville, Georgia

  • GSK Investigational Site

    Coeur d'Alene, Idaho

  • GSK Investigational Site

    Lafayette, Indiana

  • GSK Investigational Site

    Olathe, Kansas

  • GSK Investigational Site

    Topeka, Kansas

  • GSK Investigational Site

    Madisonville, Kentucky

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Sunset, Louisiana

  • GSK Investigational Site

    Cadillac, Michigan

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Albuquerque, New Mexico

  • GSK Investigational Site

    Larchmont, New York

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Dayton, Ohio

  • GSK Investigational Site

    Medford, Oregon

  • GSK Investigational Site

    Beaver, Pennsylvania

  • GSK Investigational Site

    Erie, Pennsylvania

  • GSK Investigational Site

    Phoenixville, Pennsylvania

  • GSK Investigational Site

    Gaffney, South Carolina

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Pelzer, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    Rapid City, South Dakota

  • GSK Investigational Site

    Johnson City, Tennessee

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Kingwood, Texas

  • GSK Investigational Site

    Abingdon, Virginia

  • GSK Investigational Site

    Newport News, Virginia

  • GSK Investigational Site

    Richmond, Virginia

  • GSK Investigational Site

    Dimitrovgrad, Bulgaria

  • GSK Investigational Site

    Pleven, Bulgaria

  • GSK Investigational Site

    Plovdiv, Bulgaria

Showing 40 of 165 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.